ncRNA basic information
ncRNA ID:
MIMAT0000077
ncRNA Database:
miRBase
ncRNA Name:
miR-22-3p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
NET1
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00445 (APRD00361)
Drug Name:
Epirubicin hydrochloride
Drug Method:
In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients.
Drug Response:
resistant
Cancer basic information
Cancer:
bladder cancer
Tissue/Cell:
cell line ( 5637,T24,m-Uc-3, J82,H-bc)
Other information
Title:
miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells.
Journal:
Oncol Rep
Published:
2018
PubMed ID:
29620229